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Abstract
Introduction: Patients with high-risk superficial transitional cell carcinoma (TCC) of the bladder have a
lifelong risk of progression and require particular attention. Intravesical Bacillus Calmette-Guerin (BCG)
is recommended as a first-choice adjuvant treatment to reduce the risk of progression of high-grade tumors
and carcinoma in situ (CIS).
Objectives: To evaluate the need for routine transurethral bladder biopsy from the site of previously resected
tumor three months following intravesical BCG therapy, even if the urine cytology and cystoscopy were
both negative.
Subjects and methods: A prospective study was carried out on 45 patients of both genders presenting with
superficial bladder cancer. All patients received a six-week course of intravesical BCG. The mean age of
the patients was 59 (range 33–80) years. Three months following resection, urine cytology was negative
in all patients. Cystoscopy was then performed and although it was negative for any suspicious lesions, a
routine biopsy from the previous resection site was taken.
G instillation was T1G1 in 20 patients (44%), T1G2 in 12 patients (27%) and
hree patients (7%) had a positive bladder biopsy for malignancy at follow-upResults: The indication for BC
TaG2 in eight patients (18%). T∗ Corresponding author.
-mail address: mohamed.galalelsheikh@gmail.com (M.G. El-Sheikh).
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despite the negative cystoscopy and cytology. There were no statistically significant differences between
patients with positive and those with negative biopsies with regard to the stage and grade of the tumor
before resection or the number of resected lesions. The original pathology of the three positive patients was
T1G1 (two patients) and T1G2 (one patient). The pathology after BCG treatment was the same as before
instillation, T1G1 (two patients) and T1G2 (one patient).
Conclusion: Until more studies on larger numbers of patients are done, a routine biopsy from the site of
previously resected tumor at the time of check cystoscopy may improve the detection of tumor recurrence.
© 2012 Production and hosting by Elsevier B.V. on behalf of Pan African Urological Surgeons’ Association.
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course of intravesical BCG therapy was given. Three months later,
they were re-evaluated by urine cytology and cystoscopy. None of
them showed recurrence.
Table 1 Initial pathology before BCG therapy (stage and grade).
Number Percentage (%)
CIS 1 2
TaG2 8 18
TaG3 1 2
T1G1 20 44
Rec. TaG1 1 2
ND licIntroduction
Patients with high-risk non-muscle invasive transitional cell carci-
noma (TCC) of the bladder have a lifelong risk of progression and
require particular attention [1,2]. Intravesical Bacillus Calmette-
Guerin (BCG) instillation is recommended as a first-choice
treatment to reduce the risk of progression of high-grade tumors
as well as carcinoma in situ (CIS) [3].
Although one-third of patients are cured after intravesical BCG treat-
ment, one-third of patients progress to infiltrating disease and the
remaining one-third show recurrence [4–6].
Diagnosis of recurrence of a high-grade tumor is very important
because it indicates a worse prognosis which may change the deci-
sion to perform cystectomy [7].
The effect of BCG therapy following the resection of superficial
bladder cancer can be evaluated by urine cytology, cystoscopy and
a bladder biopsy. Because of the invasiveness of bladder biopsy and
its cost, some urologists do not perform it routinely, although others
support the concept of a routine biopsy regardless of the findings on
cystoscopy and cytology [6].
In the literature, the sensitivity of urine cytology in diagnosing recur-
rence of high-risk tumors varies from 44% to 97% [8,9]. Studies have
reported that following treatment with intravesical BCG, perform-
ing a routine biopsy can be avoided if both the urine cytology and
cystoscopy were negative [10,11].
The aim of our study was to evaluate the need for routine biopsy
from the site of previously resected superficial bladder tumor three
months following resection and intravesical BCG therapy in the
presence of negative urine cytology and cystoscopy.
Patients and methods
This is a prospective study carried out in the period between
December 2008 and February 2010 on 45 patients with superficial
bladder cancer of both genders presenting to both Nasser Institute
and the urology department of Cairo University.
All patients presented with hematuria and irritative voiding symp-
toms. The patients were investigated by urine analysis, serum
creatinine, abdominal and pelvic ultrasound (US) and intravenous
Open access under CC BY-NC-urography (IVU). The diagnosis was then made by cystoscopy and
complete transurethral resection of the lesion. Under completely
aseptic conditions, all patients received intravesical BCG in a dose
of 90 mg diluted in 50 ml normal saline that was instilled intravesi-ally using a transurethral Foley catheter. The patients were asked to
etain the BCG solution in the bladder for 1 h. This instillation was
hen repeated weekly for six successive weeks. Three months after
nitial resection, urine cytology was performed on all patients and
hey were scheduled for check cystoscopy. At the time of cystoscopy,
routine biopsy was taken from the site of previously resected tumor.
ll patients included in the study had negative urine cytology and
ystoscopy at the time of biopsy.
esults
he mean age of the 45 patients was 59.3 years (range 33–80 years).
outine biopsy from the previously resected site was positive in
hree patients (7%) despite having negative urine cytology and the
ystoscopy being clear of any suspicious lesions.
oncerning these three patients with positive bladder biopsy, the
athology of the originally resected tumor was T1G1 in two patients
nd T1G2 in the third patient. Table 1 shows the pathology of the
riginal tumors before BCG instillation.
he pathology result of the biopsies taken from the site of the
reviously resected tumor is shown in Table 2.
here were no statistically significant differences between patients
ith positive and negative biopsies with regard to the stage and grade
f the tumor before resection, or the number of resected lesions
Tables 3–5).
egarding the three patients with positive biopsies, another six-week
ense.T1G3 2 5
T1G2 12 27
Total 45 100
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Table 2 Pathology after resection and 6 weekly intravesical BCG
instillations.
Frequency Number Percentage (%)
Cystitis 19 42
Cystitis with dysplasia 12 27
Cystits cystica and cystitis glandularis 3 7
Granuloma 1 2
Non-specific fibrosis 2 4
Polypoid cystitis 5 11
TCC 3 7
Total 45 100
Table 3 T stage of the studied sample in relation to biopsy result.
T stage × group
T stage Group
Negative Positive Total
CIS
Count 1 0 1
% within group 2% 0% 2%
T1
Count 31 3 34
% within group 74% 100% 76%
Ta
Count 10 0 10
% within group 24% 0% 22%
Total
Count 42 3 45
% within group 100% 100% 100%
Table 4 Grading of the studied sample in relation to biopsy result.
Grade × group
Grade Group
Negative Positive Total
G1
Count 19 2 21
% within group 46% 67% 48%
G2
Count 19 1 20
% within group 46% 33% 45%
G3
Count 3 0 3
% within group 7% 0% 7%
Total
Count 41 3 44
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Table 5 Number of lesions of the studied sample in relation to
biopsy results.
No. of lesion × group
No. of lesions Group
Negative Positive Total
1
Count 37 3 40
% within group 88% 100% 89%
2
Count 4 0 4
% within group 10% 0% 9%
3
Count 1 0 1
% within group 2% 0% 2%
Total
Count 42 3 45
% within group 100% 100% 100%
Table 6 Comparison between our study and other studies.
Total number
of cases
No. of +ve
bladder biopsies
Dalbagni et al. [13] 81 1 (1%)
Skemp and Fernandes [14] 41 1 (2%)
Guy et al. [16] 76 0 (0%)
Murakami et al. [15] 48 1 (2%)
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b% within group 100% 100% 100%
iscussionhe management of patients with superficial papillary TCC of the
ladder has recently become controversial regarding whether to
erform a routine transurethral bladder biopsy at the time of the
T
b
aHara et al. [12] 63 10 (15.9%)
Our study, 2012 45 3 (7%)
rst follow-up cystoscopy, in order to increase the sensitivity of
ystoscopy.
n our study, three patients (7%) out of 45 patients with nega-
ive urine cytology and cystoscopy demonstrated a positive bladder
iopsy from the site of the previously resected tumor (Table 6).
lthough urine cytology in the patients with positive biopsies was
egative, the pathology revealed a high-risk superficial urothelial
umor. According to Hara and his colleagues, this false-negative
esult may be attributed to the effect of intravesical BCG therapy
hich decreases the sensitivity of urine cytology [12].
n 1999, Dalbagni et al. [13] investigated the need for doing a routine
ladder biopsy three months following resection and BCG instilla-
ion. They concluded that there is no need to perform a biopsy if
ystoscopy was normal and the urine cytology was negative. In our
tudy no biopsies were positive in 37 patients with cystoscopy show-
ng mucosal erythema and negative cytology. Only one patient out
f 13 with negative cystoscopy had a positive biopsy.
lthough Highshaw et al. [10] did not perform a cytological exam-
nation, they recommended performing a biopsy only in those
atients with suspicious findings on cystoscopy.
kemp and Fernandes [14] had only one patient (2%) with a positive
iopsy out of 41 patients with negative cystoscopy and cytology.
hey concluded that at three-month post-BCG therapy, bladder
iopsy can be avoided in those patients with a negative cystoscopy
nd urine cytology, thus avoiding more cost and morbidity.
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In a study by Guy et al. [16], the sensitivity of cytology and cys-
toscopy for detecting recurrence after intravesical BCG instillation,
was 56% and 87.5% respectively, while the specificity of cytology
and cystoscopy was 56% and 81.6% respectively. By combining the
two examinations, sensitivity reached 100% and specificity reached
76%. Seventy-six patients had a negative cytology and cystoscopy
and none of them had tumor recurrence on biopsy. They concluded
that there is no need to perform a bladder biopsy when cystoscopy
and cytology are both negative.
Murakami et al. [15] reported no necessity to perform a routine
bladder biopsy in patients who do not have a visible tumor on cys-
toscopy and negative urine cytology. Of 48 patients with negative
cystoscopy and urine cytology, only one patient (2%) had a positive
bladder biopsy.
Hara et al. [12] reported that performing routine bladder biopsy and
urine cytology helped in the early detection of BCG-resistant cancer
in ten (16%) out of 63 patients who had a normal appearing bladder
mucosa on cystoscopy and negative cytology.
Conclusion
Due to the relatively small number of patients in this study and
in similar published studies, more research is required to answer
the question whether to perform a routine biopsy at the site of
a previously resected tumor at the time of the first follow-up
cystoscopy after BCG treatment. Until then, we recommend com-
bining routine biopsy with cytology and cystoscopy to increase
the sensitivity of early detection of BCG failures and tumor recur-
rence.
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